Urotensin II levels in patients with inflammatory bowel disease

Alicic, Damir; Martinović, Dinko; Rušić, Doris; Živković, Piero Marin; Hadjina, Ivana Tadin; Vilović, Marino; Kumrić, Marko; Tokic, Daria; Šupe‐Domić, Daniela; Lupi-Ferandin, Slaven; Božić, Joško

doi:10.3748/wjg.v27.i36.6142

Cited by 8 publications

(7 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was previously established that U-II is one of the most potent vasoconstrictors contributing to increased peripheral resistance but also exerting effects on cardiac function [ 17 ]. These findings have been confirmed in several studies in the adult population where a clear association between U-II and hypertension has been shown [ 23 , 40 , 41 , 42 , 47 ]. A genetic study confirmed that S89N single-nucleotide polymorphism of the U-II gene plays a key role in the development of essential hypertension which possibly explains the independent association of elevated U-II levels in obese subjects with a positive family history of high blood pressure in our study [ 48 ].…”

Section: Discussionsupporting

confidence: 75%

“…Several studies connect U-II with the pathophysiological cascade of atherosclerosis and low-grade inflammation, which is one of the leading pathological pathways in the development of MS [ 3 , 24 , 27 , 41 ]. In a recent study in patients with inflammatory bowel disease, a positive correlation between U-II and high sensitivity C-reactive protein, a well-established biomarker of low-grade inflammation, has been observed [ 42 ]. Several studies demonstrated a possible association of U-II with indices of insulin resistance, hyperinsulinemia, and impaired glucose tolerance in hypertensive patients [ 3 , 27 , 43 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Urotensin-II in Obesity and Metabolic Syndrome in Pediatric Population

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: Urotensin-II (U-II) is a short cyclic peptide that is widely recognized as one of the most potent vasoconstrictors. U-II plays a role in the pathophysiology of MS, participating in the development of essential hypertension, insulin resistance, hyperglycemia, and a proinflammatory state. Methods: This study comprised 52 obese children and adolescents with a body mass index (BMI) z score > 2, aged 10 to 18 years. Serum levels of U-II were assessed using an enzyme-linked immunosorbent assay along with other standard biochemical parameters. Results: Elevated serum levels of U-II were recorded in the group of obese subjects with MS when compared with the group of obese subjects without MS (4.99 (8.97–3.16) vs. 4.17 (5.17–2.03) ng/mL, median and IQR, p = 0.026). Furthermore, a subgroup of study subjects with high blood pressure had significantly higher U-II levels in comparison with the normotensive subgroup (4.98 (7.19–3.22) vs. 3.32 (5.06–1.97) ng/mL, p = 0.027), while the subgroup with a positive family history of high blood pressure had significantly higher U-II levels when compared with subjects who had a negative family history of elevated blood pressure (5.06 (6.83–4.45) vs. 3.32 (6.13–2.21) ng/mL, p = 0.039). Conclusions: To the best of the author’s knowledge, this is the first study on the levels of U-II in obese children and adolescents, including a possible link to MS.

show abstract

Section: Discussionsupporting

confidence: 75%

Section: Discussionmentioning

confidence: 99%

The Role of Urotensin-II in Obesity and Metabolic Syndrome in Pediatric Population

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…It has been demonstrated how the MedDiet promotes a healthy intestinal microbiota and modulates the pathogenesis and course of IBD [70][71][72][73][74]. On the other hand, clinical trials concerning specific parts of the MedDiet, like olive oil, and patients with IBD are very scarce.…”

Section: Evidence From Human Studiesmentioning

confidence: 99%

Effects of Olive Oil and Its Components on Intestinal Inflammation and Inflammatory Bowel Disease

et al. 2022

Self Cite

View full text Add to dashboard Cite

With the rising global burden of inflammatory bowel disease (IBD) and the rising costs of novel biological drugs, there is an increasing need for dietary approaches and functional foods that could modulate the course of IBD. The Mediterranean diet has proven to be efficacious in managing chronic inflammatory diseases, and recent studies have also shown its benefits in the setting of IBD. Since olive oil and its compounds have been shown to provide a considerable anti-inflammatory effect, in this review, we aim to discuss the latest evidence concerning the impact of olive oil and its bioactive compounds on IBD. Numerous preclinical studies have exhibited solid evidence on the mechanisms by which polyphenol-rich extra-virgin olive oil (EVOO) or specific polyphenols like hydroxytyrosol (HT) provide their anti-inflammatory, antioxidative, antitumour, and microbiota-modulation effects. Accordingly, several human studies that explored the effects of olive oil on patients with IBD further confirmed the evidence brought forward by preclinical studies. Nevertheless, there is a need for larger-scale, multicentric, randomized control trials that would finally elucidate olive oil’s level of efficacy in modulating the course of IBD.

show abstract

“…We read the observational study reported by Alicic et al [ 1 ], who have convincingly shown the role of elevated urotensin II (U-II) level in patients with inflammatory bowel disease (IBD). IBD comprising Crohn’s disease (CD) and ulcerative colitis (UC) is a multifactorial condition of relapsing chronic inflammation in the gastrointestinal tract with an unpredictable course[ 2 ].…”

Section: To the Editormentioning

confidence: 99%

“…Alicic et al [ 1 ] compared the blood level of U-II in IBD patients and healthy controls, and investigated the association of U-II levels with the anthropometric, clinical and biochemical parameters. The study included 50 adult patients with prediagnosed IBD (24 with UC and 26 with CD) and 50 healthy, age- and gender-matched controls.…”

Section: To the Editormentioning

confidence: 99%

Urotensin II level is elevated in inflammatory bowel disease patients

Zhang¹,

Chen²

2022

WJG

View full text Add to dashboard Cite

It was reported that the urotensin II (U-II) level in inflammatory bowel disease (IBD) patients are significantly higher than in controls. To provide future guidance for the management of cardiovascular risk factors in IBD patients, the sample size of the current study appears to be limited, and more clinical samples to compare U-II levels in IBD patients and controls are needed. This will clarify the possible roles of inflammation factors and related signaling pathways (like EPK1/2, NF-κB and Rho/ROCK) in the pathophysiology of IBD. Therefore, large multicenter studies should be done to confirm the findings and underlying mechanisms in the future.

show abstract

Urotensin II levels in patients with inflammatory bowel disease

Cited by 8 publications

References 44 publications

The Role of Urotensin-II in Obesity and Metabolic Syndrome in Pediatric Population

The Role of Urotensin-II in Obesity and Metabolic Syndrome in Pediatric Population

Effects of Olive Oil and Its Components on Intestinal Inflammation and Inflammatory Bowel Disease

Urotensin II level is elevated in inflammatory bowel disease patients

Contact Info

Product

Resources

About